Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-040062
Filing Date
2020-08-13
Accepted
2020-08-13 16:46:54
Documents
54
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q etnb-10q_20200630.htm 10-Q 2895740
2 EX-31.1 etnb-ex311_6.htm EX-31.1 17366
3 EX-31.2 etnb-ex312_9.htm EX-31.2 17378
4 EX-32 etnb-ex32_8.htm EX-32 15602
  Complete submission text file 0001564590-20-040062.txt   6181749

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT etnb-20200630.xml EX-101.INS 788520
6 XBRL TAXONOMY EXTENSION SCHEMA etnb-20200630.xsd EX-101.SCH 39646
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE etnb-20200630_cal.xml EX-101.CAL 31720
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE etnb-20200630_def.xml EX-101.DEF 160377
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE etnb-20200630_lab.xml EX-101.LAB 339697
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE etnb-20200630_pre.xml EX-101.PRE 263068
Mailing Address 535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105
Business Address 535 MISSION STREET 14TH FLOOR SAN FRANCISCO CA 94105 4155004614
89bio, Inc. (Filer) CIK: 0001785173 (see all company filings)

EIN.: 831114349 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39122 | Film No.: 201099961
SIC: 2834 Pharmaceutical Preparations